ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatmentDariusz M. Kowalski, David Planchard, Sergey Orlov et al.|Annals of Oncology|2018Cited by 17